The Future of Myeloproliferative Neoplasm Treatment
The panelists conclude their discussion by highlighting investigational agents to look forward to.
Clinical Scenario: A 74-Year-Old with Cytopenic Myelofibrosis
Rami Komrokji, MD, presents to the panel a second clinical scenario of a 74-year-old with cytopenic myelofibrosis.
Myelofibrosis Treatment Approaches after Disease Progression
A look at the potential treatment options for a patient with myelofibrosis who progresses after first-line therapy.
Clinical Scenario: A 67-Year-Old with Myelofibrosis
Key opinion leaders discuss how they would approach treating a 67-year-old with myelofibrosis, presenting with splenomegaly.
Management of Accelerated Phase Myeloproliferative Neoplasms
Drs Palmer and Mesa explain the challenges of treating accelerated phase myeloproliferative neoplasms.
Novel Agents Under Investigation for Myelofibrosis
The panel reviews other exciting novel agents under investigation for myelofibrosis treatment.
Momelotinib in Myelofibrosis Treatment: Updates from ASCO 2022
Ruben Mesa, MD, discusses updates on the novel agent momelotinib from an abstract he presented at ASCO 2022.
Efficacy and Safety of JAK Inhibitors for Myelofibrosis
Jamile Shammo, MD, FACP, explains the efficacy and safety of the 3 approved therapies for myelofibrosis.
New JAK Inhibitors in Myelofibrosis Treatment
Experts discuss data on the recently approved agents fedratinib and pacritinib for myelofibrosis treatment.
Ruxolitinib in Myelofibrosis Treatment and the COMFORT Trials
A review of data on the use of the JAK inhibitor ruxolitinib for patients with myelofibrosis.
Risk Stratification for Myelofibrosis
The panel has a conversation on risk stratification for myelofibrosis and how it individualizes their treatment approaches.
Myeloproliferative Neoplasms: Myelofibrosis
Dr Jamile Shammo explains the process of diagnosing myelofibrosis and highlights the importance of bone marrow biopsies.
Assessing Symptom Burden and Quality-of-Life for Myeloproliferative Neoplasms
A discussion on assessing symptom burden and quality of life for patients with essential thrombocythemia or polycythemia vera.
PTG-300 Therapy for Phlebotomy-Dependent Polycythemia Vera
Ruben Mesa, MD, details an abstract presented at ASCO 2022 on an investigational agent filling an unmet need in polycythemia vera.
Treatment Options for Polycythemia Vera
An overview of the treatment options for patients with polycythemia vera.
Myeloproliferative Neoplasms: Polycythemia Vera
Jamile Shammo, MD, FACP, FASCP, defines polycythemia vera and explains the process for diagnosis and risk stratification.
Managing Patients with Essential Thrombocythemia
Dr Ruben Mesa describes how he treats patients with essential thrombocythemia and the available treatment options.
Myeloproliferative Neoplasms: Essential Thrombocythemia
Jeanne Palmer, MD, explains essential thrombocythemia and how it’s diagnosed.
Future Directions in the Treatment of Polycythemia Vera
A thought leader in hematologic malignancies provides key insights into the future of treatment for polycythemia vera by considering the potential role of treatment sequencing or combination therapy.
Ruxolitinib in PV: The RESPONSE-2 Trial
Jamile Shammo, MD, FASCP, FACP, continues her discussion of ruxolitinib for polycythemia vera by examining the results of the RESPONSE-2 trial and sharing personal experience managing toxicity in clinic.
Dr. Krop on Trastuzumab Deruxtecan in HER2+ Metastatic Breast Cancer
Breast Cancer Index Risk Scores Are Prognostic for Premenopausal Women With HR+ Breast Cancer Receiving Adjuvant Endocrine Therapy
Black Women With HR+ Breast Cancer Have Worse Outcomes, Despite Similar Recurrence Scores
Benefit of Adjuvant Abemaciclib Increases at 4-Year monarchE Landmark Analysis for Patients With HR+/HER2– High-Risk Early Breast Cancer
2 Clarke DriveSuite 100Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.